靶向Tec激酶ITK可缓解T细胞介导的结肠炎并有望治疗溃疡性结肠炎
该研究在223例炎症性肠病患者中观察到溃疡性结肠炎(UC)而非克罗恩病黏膜CD4+ T细胞中pITK表达扩增且与疾病严重度相关;环孢素A(CsA)可抑制培养CD4+ T细胞中ITK活化;在3种小鼠结肠炎模型中,遗传失活Itk或药物阻断ITK均可预防或抑制已建立的结肠炎,ITK通过NFATc2信号调控黏膜Th2和Th17淋巴细胞的凋亡与活化。
要点
- UC患者黏膜pITK表达CD4+ T细胞扩增且与疾病严重度相关
- CsA抑制培养CD4+ T细胞中ITK活化
- 遗传或药物靶向ITK在3种小鼠结肠炎模型中预防或治疗结肠炎
核心结论
- ITK活化在UC中被检测到,选择性靶向ITK通过驱动黏膜炎症消退成为治疗慢性肠道炎症及潜在UC的有吸引力的方法。
研究设计与样本
- 分析223例炎症性肠病患者并评估ITK活性及CsA的功能效应。
- 使用3种独立的小鼠结肠炎模型研究ITK的功能作用。
- 通过药理学抑制剂和基因工程小鼠阻断ITK活性。
- 读出参数包括微型内镜、组织病理学、黏膜T细胞凋亡和细胞因子产生。
主要发现
- UC而非克罗恩病中pITK表达黏膜CD4+ T细胞扩增,且与疾病严重度相关。
- CsA抑制培养CD4+ T细胞中ITK活化及邻近T细胞受体信号复合物的含钙调磷酸酶微簇。
- CsA抑制实验性结肠炎的能力关键依赖于ITK。
- 通过基因打靶或诱导等位基因敏感Itk突变体遗传失活Itk在3种结肠炎模型中预防实验性结肠炎。
- 药理学ITK阻断剂治疗抑制已建立的结肠炎。
临床怎么用
- 选择性靶向ITK可能作为治疗慢性肠道炎症及潜在UC的策略,通过驱动黏膜炎症消退。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The molecular checkpoints driving T cell activation and cytokine responses in ulcerative colitis (UC) are incompletely understood. Here, we studied the Tec kinase ITK in UC. METHODS: We analyzed patients with inflammatory bowel disease (n = 223) and evaluated ITK activity as well as the functional effects of cyclosporine-A (CsA). In addition, 3 independent murine colitis models were used to investigate the functional role of ITK. Finally, the activity of ITK was blocked via pharmacological inhibitors and genetically engineered mice. Readout parameters were mini-endoscopy, histopathology, mucosal T cell apoptosis, and cytokine production. RESULTS: We found an expansion of pITK-expressing mucosal CD4+ T cells in UC rather than Crohn's disease that correlated with disease severity. CsA suppressed activation of ITK in cultured CD4+ T cells and calcineurin-containing microclusters adjacent to the T cell receptor signaling complex. Functionally, the capacity of CsA to suppress activity of experimental colitis was critically dependent on ITK. Genetic inactivation of Itk via gene targeting or induction of allele-sensitive Itk mutants prevented experimental colitis in 3 colitis models, and treatment with pharmacological ITK blockers suppressed established colitis. In addition, ITK controlled apoptosis and activation of mucosal Th2 and Th17 lymphocytes via NFATc2 signaling pathways. CONCLUSIONS: ITK activation was detected in UC and could be down-regulated in cultured T cells by CsA administration. Selective targeting of ITK emerges as an attractive approach for treatment of chronic intestinal inflammation and potentially UC by driving resolution of mucosal inflammation.
引用
- Lechner K, Mott S, Al-Saifi R, et al. Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis. Gastroenterology. 2021. PMID: 34224738. doi:10.1053/j.gastro.2021.06.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。